SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech firesales
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (3556)6/19/2018 11:54:28 AM
From: quidditch   of 3661
 
yes, congrats to SRPT holders:

as long as Tuck injected SRPT in his firesale thread and also noted a
firesale because of SRPT's results, a further question, albeit probably
better suited for Peter's thread directly:

Obviously, FGEN's 3019 MOA vs CCN2 is an entirely
distinct MOA and approach from SRPT's GT, should the latter be
considered as primary therapy (assuming development continues to be positive)
or will DMD practitioners advocate pamrevlumab therapy in conjunction?

That is to ask whether it is likely the two approaches can be used in
complementary fashion? Too early on either account to posit?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News